Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. Unlike 1,4-benzodiazepines, it has a more favorable profile regarding sedation and cognitive impairment. It is a Schedule IV controlled substance.
## Primary Indications
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS). Off-label use includes refractory epilepsy and status epilepticus.
## Adult Dosing
* **Initial Dose:** 10 mg/day, titrated over 2 weeks to target dose.
* **Maintenance Dose:** 20 mg/day (given in two divided doses).
* **Max Dose:** 40 mg/day (only for patients > 30 kg, administered in divided doses).
## Pediatric Dosing (≥ 2 years of age)
Dosing is weight-based for patients ≤ 30 kg:
* **Initial Dose:** 5 mg/day.
* **Maintenance Dose (after 7 days):** 0.25–0.5 mg/kg/day, titrated up to 1 mg/kg/day (max 20 mg/day).
* **Patients > 30 kg:** Follow adult dosing guidelines.
## Dose Adjustments
* **Hepatic Impairment:** Reduce initial and maintenance doses by 50% in patients with moderate to severe hepatic impairment (Child-Pugh Class B or C).
* **Renal Impairment:** No specific adjustment required; use with caution.
* **CYP2C19 Poor Metabolizers:** Start at lower dose and titrate conservatively, as clobazam levels may double.
## Contraindications
* Known hypersensitivity to clobazam.
* History of severe allergic reactions (e.g., Stevens-Johnson Syndrome).
## Adverse Effects
* **Common:** Somnolence, sedation, lethargy, pyrexia, constipation, drooling/sialorrhea.
* **Serious:** Severe skin reactions (SJS/TEN), respiratory depression (especially when combined with opioids), suicidal ideation, and withdrawal seizures upon abrupt cessation.
## Key Drug Interactions
* **Opioids:** Concomitant use significantly increases risk of profound sedation, respiratory depression, coma, and death.
* **CYP2C19 Inhibitors:** (e.g., fluconazole, fluvoxamine) Increase clobazam/N-desmethylclobazam levels.
* **Stiripentol:** Significantly increases clobazam levels; requires a mandatory 50% dose reduction of clobazam.
* **Hormonal Contraceptives:** Clobazam may decrease the efficacy of contraceptives metabolized by CYP3A4.
## Monitoring
* **Respiratory Status:** Especially during initiation or dose escalation.
* **Behavioral:** Monitor for onset or worsening of depression, suicidal ideation, or unusual changes in behavior.
* **Dermatologic:** Educate patients to report skin rash or mucosal lesions immediately.
## Clinical Pearls
* **Tapering:** Never discontinue abruptly due to the risk of status epilepticus and withdrawal symptoms. Taper slowly over several weeks.
* **Administration:** Oral suspension should be shaken well. Tablets may be crushed and mixed with applesauce.
* **Active Metabolite:** Clobazam is converted to N-desmethylclobazam, which has significant anticonvulsant activity and a longer half-life than the parent drug.
***
*Disclaimer: This information is for educational purposes only. Drug information, protocols, and clinical guidelines change frequently. Always consult the most current official prescribing information (package insert) and institutional guidelines before prescribing or administering medication.*
